Teva is getting ready to close the first chapter of its “pivot to growth” strategy.
The company’s restructuring has involved manufacturing site closures, a shift away from some lower-margin generics, and more recently, plans to sell off its API unit. The first quarter of 2024 marked Teva’s fourth consecutive quarter of revenue growth, CEO Richard Francis told investors on Wednesday, as he looks toward the next phase in the strategy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.